Daniel B Costa
Costa, Daniel B.
VIAF ID: 8146573809638101333 (Personal)
Permalink: http://viaf.org/viaf/8146573809638101333
Preferred Forms
- 100 1 _ ‡a Costa, Daniel B.
- 100 0 _ ‡a Daniel B Costa
4xx's: Alternate Name Forms (2)
Works
Title | Sources |
---|---|
Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation. | |
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. | |
ALK inhibitors: plateauing systemic and intracranial activity? | |
ALK translocation in non-small cell lung cancer with adenocarcinoma and squamous cell carcinoma markers. | |
Alterations of tumor microenvironment by carbon monoxide impedes lung cancer growth | |
Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. | |
Case of fatal sickle cell intrahepatic cholestasis despite use of exchange transfusion in an African-American patient. | |
CCAAT/enhancer binding protein β is dispensable for development of lung adenocarcinoma. | |
Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer | |
Clinical experience with crizotinib in patients with advanced ALK-Rearranged non–small-cell lung cancer and brain metastases | |
The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-Review | |
CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. | |
Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling | |
Diabetes mellitus as the presenting feature of extrahepatic cholangiocarcinoma in situ: case report and review of literature. | |
Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations. | |
A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. | |
EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patients. | |
Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells. | |
Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice | |
Germline mutations in driver oncogenes and inherited lung cancer risk independent of smoking history. | |
Hyperglycemia and biliary tract adenocarcinoma. | |
Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer. | |
Improvement of Type 2 Diabetes in a Lung Cancer Patient Treated With Erlotinib | |
In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer | |
Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis | |
Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches | |
Modern treatment of lung cancer: case 3. Non-metastatic bilateral F-18 fluorodeoxyglucose avid adrenal glands in non-small-cell lung cancer. | |
Molecular testing in lung cancer: the time is now. | |
More than just an oncogene translocation and a kinase inhibitor: Kevin's story. | |
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response | |
A novel mutation in the last exon of ATRX in a patient with alpha-thalassemia myelodysplastic syndrome. | |
A novel splicing mutation of the alpha-spectrin gene in the original hereditary pyropoikilocytosis kindred. | |
De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors. | |
Patterns of care for non-small-cell lung cancer at an academic institution affiliated with a national cancer institute-designated cancer center. | |
Pneumococcemia as the presenting feature of multiple myeloma | |
Polymorphism of the CYP1A1*2A gene and susceptibility to lung cancer in a Brazilian population. | |
Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers | |
Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. | |
Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas. | |
Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. | |
The rapidly evolving landscape of biomarker testing in non-small cell lung cancer | |
Recurrent Infections in Multiple Myeloma | |
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. | |
The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer | |
Serum concentrations of Erlotinib at a dose of 25 mg daily. | |
Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice. | |
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer | |
Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer | |
Time to SARS-CoV-2 Clearance Among Patients with Cancer and COVID-19 | |
To re-treat or not with gefitinib/erlotinib: This is the question for tyrosine kinase inhibitor-responsive lung cancers that progress | |
Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung | |
Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M. | |
β-catenin contributes to lung tumor development induced by EGFR mutations |